Efficacy and Safety of DLBS3233 in Prediabetic Patients
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
This is a 2-arm, prospective, double blind, randomized, and controlled clinical study for 12
weeks of therapy to investigate clinical efficacy and safety of DLBS3233.
It is hypothesized that DLBS3233 will delay the progress of beta-cell dysfunction as measured
by the improvement of prandial (particularly the first phase) insulin secretion as well as
insulin resistance in prediabetic subjects which may prevent the conversion of prediabetes
into type 2 diabetes mellitus.